Novartis : Kymriah Shows Strong Responses In High-risk Patients With Relapsed Or Refractory FL
11/12 19:43
(RTTNews) - Novartis' (NVS) Kymriah or tisagenlecleucel demonstrated strong efficacy in high-risk patients with relapsed or refractory follicular lymphoma, as per a subgroup analysis from an about 17-month median follow-up of the pivotal Phase II ELARA study....